Recorded June 28, 2022
The targeted therapy Bruton tyrosine kinase inhibitors (BTKi’s) have come a long way since revolutionizing CLL treatment with the arrival of ibrutinib. There are now other BTKi options such as acalabrutinib, zanubrutinib, and the next generation non-covalent BTK Inhibitor, pirtobrutinib. Join CLL Society and Dr. Matthew Davids from Dana Farber Cancer Institute to take a deep dive into different BTKi’s, how they work, how they compare to each other and other treatment options, potential side effects, and the future role of these therapies.
Welcome:
Robyn Brumble
Director of Scientific Affairs
CLL Society
Speaker:
Moderator
Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer
CLL Society
Speaker
Matthew S. Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana Farber Cancer Institute
CLL Society Resources
- Download Slides
- Evolution of BTKi’s
- Acalabrutinib vs. Ibrutinib Study
- Zanubrutinib vs. Ibrutinib Study
- Approval of Zanubrutinib
- Pirtobrutinib (LOXO 305)
- CLL Glossary
- Test Before Treat™
- Sign up for CLL Society’s This Week email
- Celebrating Long Lives Virtual 5K Event
- Please Consider Donating to CLL Society
Virtual Exhibit Resources
This program was made possible by grant support from AstraZeneca, BeiGene, Pharmacyclics, and Janssen.
